TORONTO, Sept. 26, 2018 /CNW/ - Arch Biopartners
Inc., (Arch or the Company) (TSX Venture: ARCH) (OTCQB: ACHFF)
today announced that Dalton Pharma Services (Dalton) has completed
the good manufacturing practice (GMP) glass vial filling stage for
Metablok, the Company's lead drug candidate for preventing acute
kidney injury.
Over the next six to eight weeks Dalton will be completing the
quality control process which will culminate with the release of a
clinical drug product to be used in a phase I safety trial for
Metablok.
Arch awaits the completion of ongoing toxicology and
pharmacology studies at Nucro-Technics in November before
confirming the start date of the phase I human trial.
Arch is currently finalizing the planning of the Phase I trial
including the selection of a clinical site. Arch plans to make
further disclosures when such details are confirmed.
Cardiac Surgery-Associated Acute Kidney Injury
Acute kidney injury (AKI) occurs in approximately 30% of
patients that undergo cardiac bypass surgery with 1% of patients
requiring dialysis. Currently, no specific therapies exist to
prevent AKI. Worldwide, there are over one million patients per
year that have cardiac surgery procedures.
AKI represents an additional challenge in patients recovering
from cardiac surgery as they have higher incidences of mortality,
complications in treatment course, and higher risk of complications
such as cardiovascular events and infection. Of the patients that
require dialysis because of cardiac surgery-associated AKI, many
will require lifelong dialysis which increases overall morbidity
and mortality.
Inflammation is known to contribute to AKI related to
ischemia-reperfusion and other insults to the kidney that may occur
in the course of cardiac surgery. Metablok is a
novel therapeutic agent that may protect the kidneys and
prevent AKI in patients undergoing cardiac surgery.
About Dalton:
Dalton Chemical Laboratories Inc. o/a Dalton Pharma Services is
a Health Canada approved and FDA registered cGMP contract service
provider of integrated chemistry, drug development and
manufacturing services to the pharmaceutical and biotechnology
industries. Dalton brings over 30 years of experience to their
client's projects and emphasize quality, speed and flexibility.
Dalton can accelerate a drug development program by integrating
drug discovery, formulation and process development, custom
synthesis, cGMP sterile fill/finish of liquids and powders, cGMP
API manufacturing and/or dosage form manufacturing and Accelerated
Stability Testing, all at a single location that helps Dalton to be
adaptable, flexible and cost-effective.
For Dalton's full range of in-house services
including cGMP sterile fill/finish services please
visit www.dalton.com.
CMO 2016, 2017 and 2018 Leadership Awards in the categories of
Quality, Reliability, Capabilities, Expertise, Compatibility and
Development from Life Science Leader reflects Dalton's ongoing
commitment to their clients, peers and the business community. In
2017 Dalton was re-certified as "A Great Place to Work."
About Arch Biopartners
Arch Biopartners Inc. is focused on the development of
innovative technologies that have the potential to make a
significant medical or commercial impact. Arch has
established a diverse portfolio that includes Metablok (LSALT
peptide), a potential treatment for inflammation, sepsis and cancer
metastasis; AB569, a potential new treatment for antibiotic
resistant bacterial infections in the lung, urinary tract or
wounds; and, 'Borg' peptide coatings that increase corrosion
resistance and decrease bacterial biofilm on various medical grade
metals and plastics.
For more information on Arch Biopartners, its technologies and
other public documents Arch has filed on SEDAR, please visit
www.archbiopartners.com
The Company now has 58,495,179 common shares outstanding.
Forward-Looking Statements
All statements, other than statements of historical fact, in
this news release are forward looking statements that involve
various risks and uncertainties, including, without limitation,
statements regarding the future plans and objectives of the
Company. There can be no assurance that such statements will prove
to be accurate. Actual results and future events could differ
materially from those anticipated in such statements. These and all
subsequent written and oral forward-looking statements are based on
the estimates and opinions of management on the dates they are made
and are expressly qualified in their entirety by this notice. The
Company assumes no obligation to update forward-looking statements
should circumstances or management's estimates or opinions
change.
Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
SOURCE Arch Biopartners Inc.